Promising phase 2 study for cholangiocarcinoma, a deadly cancer with very few treatment options. Data support the therapeutic potential of pemigatinib in previously treated patients with CCA who have FGFR2 fusions or rearrangements. @GABOUALFA @TheLancet
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
[Articles] Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study https://t.co/oolp1nqtka
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
RT @GABOUALFA: FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib fo…
@GABOUALFA is Pemi toxicity profile similar to Erdafitinib?
FGFR2 fusion/rearrangement cholangiocarcinoma patients hopefully will have a treatment option soon. Just in! Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study https://t.co/MXmUn
[Articles] Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study: These data support the therapeutic potential of pemigatinib in previously treated patients with… https://t.co/MeFraS